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Abstract
Background: There is paucity of data on quality of life as a dimension of treatment outcome among Visceral
Leishmaniasis and HIV coinfected patients. This study sought to explore perceived quality of life among Visceral
Leishmaniasis and HIV coinfected male migrant workers in Northwest Ethiopia.
Methods: Twenty Visceral Leishmaniasis and HIV coinfected study participants took part in the in-depth interviews
at Visceral Leishmaniasis and HIV treatment centers. Ten participants were on antiretroviral treatment (ART) and
the remaining 10 have not yet started ART. All interviews were recorded, transcribed and translated for analysis.
Data were analyzed by qualitative content analysis using Open Code software version 3.4.
Result: Participants reported on four aspects of quality of life: liveability of the environment, utility of life, life
ability of a person and appreciation of life. Respondents living environment, therapeutic side effects of Visceral
Leishmaniasis drugs, poverty and stigma negatively affected their quality of life. On the contrary, good treatment
response and financial security were reported to positively affect their quality of life.
Conclusion: Challenges related to the living environment, financial limitations and sub-optimal response of Visceral
Leishmaniasis drug and relapse of Visceral Leishmaniasis disease are factors most negatively affecting the quality
of life of Visceral Leishmaniasis and HIV coinfected patients. Micro-financing and other socio-economical support
programs should be launched to assist the unemployed males migrating to Visceral Leishmaniasis endemic and
relatively higher HIV prevalent areas to work as daily laborers. HIV prevention programs in HIV positive-living
counseling programs should target such high risk migrant workers in the endemic areas.
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Background
Human immunodeficiency virus (HIV) and Visceral
Leishmaniasis (VL; also known as “Kala-azar”) coinfec-
tion reported in 35 countries [1, 2], among which
Ethiopia carries the highest burden. Twenty three per-
cent (23%) of people with VL were also infected with
HIV in 2008, far higher than anywhere else in the world.
The affected populations are largely very poor male sea-
sonal migrant workers that travel in the harvesting
season from non endemic highlands to the cotton,
sesame and sorghum fields of Humara and Metama on
the Sudanese boarders [3, 4].
VL and HIV coinfection are associated with special
therapeutic challenges. VL-HIV coinfected patients are at
higher risk of relapse and death. Furthermore, VL
adversely affects the response to antiretroviral therapy
(ART) [5, 6]. In Ethiopia, free ART has been given to
patients since 2003 [7]. To improve quality of life (QoL), it
is vital to explore the perception and determinants of QoL.
Many studies have provided important information on
the correlates of health related quality of life (HRQoL)
during HIV infection. Several studies have documented
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significant improvements in QoL during ART [8–10].
There is however knowledge gap on the understanding
of perception of QoL of patients with VL-HIV coinfec-
tion as a treatment outcome. Thus, the aim of this study
was to explore perceived QoL among VL-HIV coinfected
migrant male-workers using qualitative method, and to
reveal the concept of QoL for people who are VL-HIV
coinfected in Ethiopian context to contribute to the
development of VL-HIV coinfected persons care model.
Methods
Study design
An in-depth qualitative, phenomenological study design
was selected to carry out searching of the lived experi-
ence and perceptions of the study subjects on the quality
of life of VL-HIV coinfected male patients that were
receiving VL treatment.
Study setting
The study was carried out at three different sites found
in Northwest Ethiopia. The first site was Abdrafi in-
patient kala-azar treatment center located in Abdrafi; at
this health center medical services are provided for pa-
tients with Leishmaniasis, VL-HIV coinfection and snake
bite. The second site was Kala-azar Treatment and
Research Center found in the University of Gondar
Hospital located in Gondar; at this center both out-
patient and inpatient medical services are provided for
patients with Leishmaniasis and VL-HIV coinfection in
addition to the comprehensive medical service from
other units in the University of Gondar Hospital. The
third site was Kahsay Aberra Hospital located in
Humera kala-azar treatment center; at this center both
outpatient and inpatient medical services are provided
for patients with Leishmaniasis, VL-HIV coinfection and
many other hospital level services. Study participants
come from different parts of kala-azar endemic areas
with a variety of cultural background in Northwest
Ethiopia. As the typical patient approach procedure,
when the patients come to the clinic, the physicians and
the health officers will do clinical and laboratory exami-
nations to diagnose the patients for kala-azar, if patients
are found to be positive for VL they will further screen
them for HIV. This allows the health workers to select
the appropriate treatment for VL-HIV coinfection.
Recruitment of participants
The study included twenty VL-HIV coinfected male pa-
tients who were attending VL treatment. Newly diag-
nosed VL-HIV coinfected patients who already started
ART and who didn’t start ART were included in this
study. We distributed invitation letters to approach the
study participants at kala-azar treatment centers of the
selected health facilities in the study area. A purposive
sample of 20 study participants, ten patients who already
started ART and the remaining ten patients didn’t start
ART, participated in the study. Study participants had
not been evaluated for quality of life before this study.
Individuals who were seriously sick and mentally dis-
abled were excluded.
Data collection and analysis
The data collection method was in-depth semi-
structured interviews. After securing written informed
consent, a topic guide was used as a prompt for ques-
tioning. The key consideration for influencing the direc-
tion of each interview was the participant’s response to
questions in terms of their individual experiences. The
principal investigator (PI) conducted the face-to-face in-
depth interviews using semi-structured guide in venues
suitable for the participants. The guide was developed in
English and translated in to Amharic (the local language)
for all participants. Interviews were recorded using audio
recorder devise in order to capture all information pro-
vided by the interviewee.
The interview was started by couple of questions pre-
pared to create rapport with the study participants.
These questions focus on the life experiences as a
migrant worker and challenges they faced when they are
diagnosed with VL-HIV coinfection. After we created a
rapport, the theme of quality of life issues was intro-
duced in subsequent interview of persons living with
VL-HIV coinfection. The interviewer probed for any
changes in personal values, responses for treatments and
goals and how they are related to quality of life.
The PI had continued interviewing participants until
no new information is provided from additional inter-
views (i.e., the point of saturation is reached). Upon
completion of each interview and based on the recorded
audio the PI developed a detailed transcription that cap-
tures all the discussion. These texts and the emerging
themes identified during the course of the interviews
were confirmed by the coauthors and issues were ad-
dressed. All the interviews were transcribed and pre-
pared for coding and thematic analysis. The typed data
were analyzed by qualitative content analysis using the
Open Code software version 3.4 (Umea University,
Umea, Sweden). The Open Code software is used as a
tool for classifying and sorting qualitative information.
The investigators scrutinized transcripts were read
multiple times in order to get general sense of the con-
tent. An inductive qualitative content analysis method
was used to analyze the data. A coding framework was
developed based on the emerging themes. Emergent cat-
egories and themes were identified based on meticulous
and systematic reading and coding of the transcripts.
Codes and sub-codes were refined during the analysis.
This was done by the PI and reviewed by the coauthors.
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Results
Among the twenty patients included in the study, ten
patients were started taking antiretroviral (ARV) drugs
in addition to the Visceral Leishmaniasis (VL) drugs dur-
ing interview. The remaining ten patients have not yet
started taking ARV drugs but were taking VL treatment.
All of the study participants were male migrant workers.
The age range of participants was from 25 to 52 years.
Emergent categories and themes were identified from
the interviews, including “Liveability of the environ-
ment” as indicators of QoL; “Utility of life”, covers re-
sponses of life expectations/goals; “Life ability”, covering
responses to VL and HIV treatments, stigma, stress and
VL relapse and appreciation of life.
Liveability of the environment
Indicators of quality of life
Quality of life was discussed in terms of wellbeing and
happiness influenced by good health, having money,
good living environment, good social relations and emo-
tional wellbeing. All of the study participants (taking
ART and not taking ART) interviewed defined QoL in a
way similar to World Health Organization (WHO) def-
inition of health as “a state of complete physical, mental
and social wellbeing and not merely absence of disease
or infirmity” [11].
One 51 year-old man, taking both VL and ARV drugs
said “QoL is about being healthy, having good energy
and enough money.” A 42 year-old man, taking both VL
and ARV drugs remarked “QoL is when one has health,
access to VL treatment centers and money. If I have
money and access to VL treatment center, I am able to
treat my VL relapse immediately; my QoL is good”. A
39 year-old man, taking only VL drug and not in ART
said “QoL is about not working in hot areas (low lands)
and having work in cold areas (high lands), having
shelter”. A 33 year-old man, taking both VL and ARV
drugs said “QoL is about having money, not doing la-
borious work, free from any substance use or abuse such
as chewing khat, smoking cigarette and drinking alcohol
and not being coinfected by VL”. Another 29 year-old
man, taking only VL drug and not in ART said “It’s
about being cured from VL, able to create my own
business and earn money and marrying a woman and
have children”.
The majority (16/20; 80%) of the study participants in
both groups mentioned availability of money is very much
vital for their wellbeing and hence a good QoL, and for ex-
ample “for me after I finished VL treatment, I don’t have
money for transport to go back to my residence. To cover
my daily expenses I need to have money” (34 year-old
man, taking only VL drug and not in ART) and “I need
money to pay my house rent, for food and to buy clothes
that are vital for sustaining my life” (42 year-old, taking
both VL and ARV drugs). One 32 year-old man, taking
both VL and ARV drugs said that “I am very much worried
about my future life after I am discharged from this VL
treatment center. Unlike previous times I don’t have
enough energy to work as a daily laborer in hot areas (low
lands) because VL infection severely weakened my body.
On the other hand, in order to do my own job, I don’t have
enough money. I am very much worried about how to get
money for my daily subsistence. It is very much difficult to
be happy and lead good QoL when you have no money”.
All of the respondents in both groups stated that good
health and money were crucial to their wellbeing and
QoL. Most of the participants were migrant daily
laborers. They were more frank when discussing money
as a source of wellbeing. For instance, one 34 year-old
migrant daily laborer resided in May-kadra district who
are taking only VL drug and not in ART said that “my
choice of living in May-kadra is because there is job
opportunity and I am able to earn money” and also one
33 year-old migrant daily laborer residing in Humera
district who are taking both VL and ARV drugs stated
“In order to sustain my income, I am working laborious
work in very hot area of Humera districts”.
Almost all (19/20; 95%) interviewees in both groups
highlighted living environment as a cornerstone of their
not wellbeing and QoL, for example “I have resided and
spent many years in very hot area because I can be easily
employed as a daily laborer in large farms and I can gen-
erate money easily. It is not suitable for health because
there are diseases like malaria and VL” (42 year-old
man, taking both VL and ARV drugs) and “I am living in
a hot and VL disease prevalent area. For this reason I
am not happy in my living environment and withstand-
ing all those problems I will continue working as a daily
laborer to sustain my income” (33 year-old man, taking
both VL and ARV drugs). One 29 year-old man taking
only VL drugs and not in ART said “I am working as a
daily laborer moving from one hot area to the other hot
area in order to generate money for my daily expenses.
Those areas I have visited were very hot and were not
suitable for health because there are different diseases
like malaria, VL and diarrheal diseases”.
Lack of happiness due to living environment was re-
ported by majority (18/20; 90%) of the respondents in
both groups. For instance, one 39 year-old man, taking
only VL drugs and not in ART said that he is fade up of
working as daily laborer in “berha”, translated as “very
hot areas or low lands”. When asked what exactly he
meant by this, he explained that these areas are
extremely hot and there are different diseases like VL.
Therefore, working in those areas were made me coin-
fected with VL and it makes me very much weak.
Social relationships including support from immediate
family reported by few (2 patients or 10%) of the
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respondents in both groups as a key to their wellbeing,
for example, “I have supportive family, my mother’s well-
being and successful friends around me makes me
happy” (52 year-old man, taking both VL and ARV
drugs) and “a good relationship with my wife and the
care I get from my brother makes me happy” (45 year-
old man, taking only VL drugs and not in ART).
Emotional stability was a concern among a few (1 patient
or 5%) of those interviewed. A 45 year-old man, taking
only VL drugs and not in ART described QoL as “Living
the life without worries is having good QoL”. As happiness
was stated by all of the participants, we asked them further
what was meant by happiness for VL-HIV coinfected pa-
tient. Happiness was seen as indicator of QoL. The main
factors remarked as a source of happiness were to get
cured from VL disease and the free treatment they got
from the treatment facilities. The other factors mentioned
as a source of happiness included financial wellbeing.
These findings were consistent across all ages and for both
groups (with and without ART) of the participant.
Almost all (19/20; 95%) of the study participants in
both groups clearly mentioned that recovering from VL
disease and the treatment centers where they have re-
ceived care were the source of their happiness. One
25 year-old man taking only VL drugs and not in ART
said “my source of happiness depends on being cured
from VL disease”. Another 34 year-old man, taking only
VL drugs and not in ART stated that “the only way to
get back my happiness depends on being cured from VL
disease”. A 33 year-old man, taking both VL and ARV
drugs remarked “my happiness entirely depends on re-
covering from VL disease. I am also very much happy by
free treatment that I got from this treatment center”.
One 41 year-old man, taking both VL and ARV drugs
said that “My source of happiness entirely depends on
the fact that I am cured from VL disease and the sup-
port I got from the treatment center. In the last 5 years I
had experienced eleven times VL relapse and in all those
relapses this treatment center was giving me free
treatment”.
All (20 patients or 100%) of the participants in both
groups were mentioned lack of economical wellbeing as
a major contributor to their unhappiness. According to
one 34 year-old man, taking only VL drugs and not in
ART said “In order to lead my life properly I need
money and money is everything. I don’t have money to
cover my daily expenses. If I don’t get money to cover
the cost of a transport from the treatment center to my
home town then I will be a beggar”. A 42 year-old man,
taking both VL and ARV drugs said “money is a source
of my happiness. For instance, if I didn’t have money I
wouldn’t reach here to follow my treatment. Hence,
when I have money in my pocket I do have a better hap-
piness. Currently I don’t have money and I feel very
much angry”. A 51 year-old man, taking both VL and
ARV drugs said “I feel very much angry when I have no
money; I am not a happy person because I don’t have
money to pay for house rent and to buy my daily food
consumption”.
Life ability
Response to VL and ARV drug treatment
Majority (14/20; 70%) of the participants in both groups
were given Liposomal amphotricine B (AmBisome, Gilead
Sciences Ltd, Paris, France) and some (6/20; 30%) received
a combination of AmBisome with oral Miltefosine for VL
treatment. Most (10/14; 71%) of the participants in both
groups who received only AmBisome reported side effects.
Those who had side effects said that they cleared within a
couple of days and that they felt much better. A 51 year-
old man, taking both AmBisome and ARV drugs said “the
first few days may be four to five days were bad, I was
unconscious for the first day, the next 3 to 4 days I had
experienced severe sweating, abdominal cramp, constipa-
tion, sense of burns around injection areas and series of
vomiting and later stabilized”. Another 25 year-old man,
taking only AmBisome and not in ART also stated “the
first couple of days were bad, I experienced series of
vomiting that included blood, lower back pain, variability
of body temperature and loss of appetite and then after
few days these were ceased”.
Two third (4/6 or 2/3rd; 67%) of the participants in
both groups who received a combination of treatment
were also reported side effects, for example, “After I
have taken VL drugs, I experienced stomachache, consti-
pation, feeling pain during urination, loss of appetite and
severe lower back pain” (34 year-old man, taking only
combination of AmBisome with oral Miltefosine and not
in ART), and “the side effects that I experienced because
of VL drugs are diarrheal disease and loss of appetite
and whenever I took Miltefosine without eating food I
felt stomachache and vomiting” (41 year-old man, taking
both combination of AmBisome with oral Miltefosine
and ARV drugs).
A 45 year-old man who is in ART and he had been ex-
perienced seven times VL relapses in the past four years
said “Among all side effects of VL treatments that I ex-
perienced during my VL relapse times; my second time
VL relapse treatment were very much severe. The drug I
had taken during this time was sodium stibogluconate
(SSG). After nine days of taking SSG I experienced that
around two liters of blood came out from my mouth
and nose and later I quit the drug and the physician
changed it to AmBisome”.
Some of the participants in ART group reported a re-
duction in therapeutic response of VL treatment and this
results high rate of relapse, for example, “I have experi-
enced six times relapse. In most cases the VL relapse
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occurs when I am starved and when I am engaged in la-
borious works in very hot areas (low lands)” (39 year-old
man, taking both VL and ARV drugs) and “Usually my
VL relapses when I am engaged in laborious work in
very hot areas” (33 year-old migrant daily laborer, taking
both VL and ARV drugs). A 41 year-old man, taking
both VL and ARV drugs remarked “In the last five years
I had experienced 11 times VL relapse because of this
reason I couldn’t manage to do work and able to gener-
ate money for my daily expenses”.
Most (8/10; 80%) of the participants who are in ART
group reported minor side effects of ARV drug and
these side effects were cleared within few days and then
they felt much better. Those who had these side effects
of ARV drug perceived the side effects as very minor
compared to the benefits of taking ARV: “The first few
days may be 2 or 3 days were bad, I felt sleep disorder
and dizziness and later stabilized” (27 year-old man, tak-
ing both VL and ARV drugs). Another 33 year-old man,
taking both VL and ARV drugs said “For the eight days
since I started ARV, I experienced bad dreams and sleep
disorder then after eight days these feelings were
ceased”. One 29 year-old man, taking both VL and ARV
drugs stated “The first eight days were bad; I had sleep
disturbance and terrible dreams which later ceased.
Sometimes I felt headache after I have taken ARV drug”.
Almost all (9/10; 90%) of participants who were not in
ART have high interest to start taking ARV drugs. The
reason of not starting ARV drugs was residence of the
participant. All (10 patients or 100%) of the participants
who have not in ART are migrated from their home
town to be employed as daily laborer in study areas.
Therefore, after they completed VL treatments they will
be linked to ART centers that are found in their perman-
ent residence or home town. A 34 year-old man, taking
only VL drugs and not in ART said “After I completed
my VL treatment, I will start ARV drug in May-kadra
health center which is found in my home town”. An-
other 36 year-old man, taking only VL drugs and not in
ART stated “Till now I didn’t start ARV drug. The rea-
son for this is I planned to start the drug in my home
town ART center”. One 42 year-old migrant daily
laborer, taking only VL drugs and not in ART said “I
have an interest to start ARV drug but I fear to commu-
nicate my HIV status to my wife. The reason for this is
my wife is very rigid and I am in deep fear that she will
not accept me. My last option will be requesting divorce
without telling my HIV status. If it is successful I will
start the drug otherwise I will not start it”.
Stigma
The majority (8/10; 80%) of the study participants who
are in ART reported stigmatization due to their HIV sta-
tus. Some (2/10; 20%) respondent’s who are in ART
seemed to have convinced themselves about their HIV
infection and didn’t worry about what other people said
or thought of them. A 42 year-old man, taking both VL
and ARV drugs said “In my village there is a trend of
disgracing a person when he is HIV infected. Because of
this reason no one knows about my HIV status and I will
keep it secret from my family, friends and the commu-
nity at large”. Another 39 year-old man, taking both VL
and ARV drugs stated “After I told my HIV status to my
best friend he refused to eat with me”. Similarly, one
32 year-old man, taking both VL and ARV drugs re-
ported that “After I disclose my HIV status to my best
friend and his wife, she refused to eat with me”.
Many of the respondents were migrant daily laborers
and they are supposed to work in group in big farm
lands – thus making clear their HIV status makes them
discriminated by the group. One 42 year-old man, taking
both VL and ARV drugs said “I used to work in a group
as a daily laborer in Abdrafi farm lands. Among the
group one of my friends knew about my HIV status.
One day in the middle of the day I felt tired and decided
to have nap. During this time my friend told the group
about my HIV status and then the group refused to eat
and work together with me”.
A few (2/10; 20%) respondent’s who are in ART re-
ported no sense of stigma. One 45 year-old man, taking
both VL and ARV drugs said “some people gave me an
advice not to take ARV drugs in front of the people but
I don’t mind if people know. I always share my experi-
ence and how good my life is with the HIV treatment. I
encourage people whom I knew to know their HIV sta-
tus and to act accordingly”. A 41 year-old man, taking
both VL and ARV drugs remarked “I don’t care if people
know my HIV status. I don’t bother about what other
people say about me”.
Stress/depression/anxiety/fear
All (20 patients or 100%) of the participants in both
group interviewed reported that they were fearful,
shocked and worried at the time of VL and HIV concur-
rent diagnosis. Though, they got support from health
care providers. A 34 year-old man, taking only VL drugs
and not in ART described his reaction after he was
tested VL and HIV coinfection “I was very much de-
pressed and stressed. I thought I was going to die”. An-
other 41 year-old man, taking both VL and ARV drugs
who had been experienced eleven times relapse said “I
am depressed and worried about my future life. The
multiple VL relapses that I have experienced make me
desperate. Many times I felt angry and stressed”. One
25 year-old man, taking only VL drugs and not in ART
said “The first couple of weeks were bad, I felt stress and
fear to die and later I stabilized quickly after VL and
HIV treatment was started”. Participants expressed
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anxiety about house rent and daily subsistence “Currently
I have no money and enough energy to work as a daily
laborer; these are my major problems,” remarked a
51 year-old man, taking both VL and ARV drugs.
Utility of life
Goals and expectations
Over a half (12 patients or 60%) of the participants in
both groups were hopeful and have set goals for their fu-
ture life. There were similarities in the desire expressed
by the majority of hopeful respondents regarding their
wish to gain enough money for creating their own job.
The participants’ future plans included relocating their
living environment to cold areas, opening mini shop to
sustain their income, building their own homes, getting
married for those that were unmarried and having chil-
dren. Plans were explained:
“I hope to make more money and opens my own
hotel” (25 year-old man, taking only VL drugs and not
in ART), “I would like to relocate from very hot area to
cold area like Gondar town; I would also like to be a
merchant and get married to have children” (33 year-old
man, taking both VL and ARV drugs), “I would like to
make more money and relocate to cold areas; I would
also open mini shop to sustain my income and I will
marry a woman of the same status” (42 year-old man,
taking both VL and ARV drugs), “I would like to change
my profession, build home in the outskirt of the town,
and buy cattle, sheep and hens so that I will get non-
laborious work” (45 year-old man, taking both VL and
ARV drugs).
A few (2/10; 20%) interviewees who are in ART have
changed habits such as chewing khat and drinking
alcohols because of frequent relapses of VL, and put
increased focus on planning for their future how not to
be coinfected with VL again. “My VL relapses were
occurred when I consecutively engaged in substance
use/abuse like khat chewing and drinking alcohol.
Therefore, in order to prevent VL relapse I have stopped
khat chewing and drinking alcohol” (39 year-old man
who was taking both VL and ARV drugs and experi-
enced six times relapse), “I used to drink alcohol and
smoke cigarette. I stopped these activities since I started
treatment. I live my life free from any substance use/
abuse to prevent VL relapse” (40 year-old man, taking
both VL and ARV drugs).
Some (8/20; 40%) of the study participants in both
groups were not hopeful about their future, for example,
“My future is dark because I don’t have enough energy
to work as a daily laborer. I am also desperate for not es-
tablishing family” (34 year-old man, taking only VL
drugs and not in ART), “I don’t have future because if I
wasn’t infected with HIV, I would have married and have
children” (45 year-old man, taking only VL drugs and
not in ART). One 41 year-old man who was taking both
VL and ARV drugs and experienced eleven times VL re-
lapse said “There is no future for me because the fre-
quent relapse of VL makes me very much week and I
have no money to lead my life and to establish family”.
Appreciation of life
QoL by VL-HIV coinfected patients was commonly ex-
plained by both groups as being cured from VL disease,
change living environment from very hot areas to cold
area town and opening mini shop to sustain their in-
come. One 34 year-old man, taking only VL drugs and
not in ART said “when coinfected patient cured from VL
disease, they have no problems and whatever they set
out to do comes out as desired like building home and
opening mini shop to sustain their income”. One
51 year-old man who was taking both VL and ARV
drugs and experienced six times relapse explain “It’s
when one prevents VL relapse, suffers no illness and has
mini shop or micro business to earn money for their
daily subsistence like eat, drink, and no worries”.
Another 33 year-old man, taking both VL and ARV
drugs said “It’s about curing from VL disease, when you
are healthy and living in cold areas. In addition, when
you have income generating means like mini shop for
making your basic needs satisfied”.
Discussion
This study showed that the VL-HIV coinfected patients
have to overcome poor QoL; and, special emphasis
should be given for the complex challenges existing in
the treatment and care of VL-HIV coinfected patients.
The findings of this research article were framed in
accordance with the Ruut Veenhoven model of “four
qualities of life” [12]. Participants’ narratives were
alluded to the concept of “liveability of the environment”,
which could be considered to explain the prevailing eco-
nomic status such as a lack of money, living environment
and the nature of their work. Moreover, “Life ability of the
person” could be defined as how capable one is able to
cope with life problems. The participants in our study dis-
cussed the side effects of VL and HIV treatments, feelings
of stigma, and stress/depression/anxiety/fear. Some of the
participants report the ineffectiveness of VL treatments
and this results a high rate of relapse. The third theme
raised was “utility of life”, which could be considered to
describe their expectations/goals of their future life. Some
of the patients remarked that relocating from their resi-
dence to cold areas and changing job are good for im-
provement of QoL. Some of the patients also said that the
future is very dark. Finally, study participants spoke of
subjective wellbeing, expressed as “life in the eyes of
beholder” [12]. Majority of the patients to appreciate and
enjoy life we should be cured from VL disease, change
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living environment and opening mini shop. Overall, QoL
was perceived in terms of cured from VL disease and
opening mini shop.
Living environment was mentioned as indicator of poor
QoL by our study participants. Living in very hot lowland
areas was a source of VL infection and hence results a
poor QoL, all of the participants reporting that their VL
infection or relapse were because of their living environ-
ment. Our finding was supported by the eco-epidemiology
study of VL in Ethiopia [13], the Humera plains in the Ti-
gray and Amhara regional states, bordering Sudan and
Eritrea, constitute the main VL endemic area in the coun-
try, contributing over 60% to the burden of VL infection.
Hence, the finding of this study also gives further evidence
on the high transmission of VL from which the clinical
cases are reported in Northwest Ethiopia.
The study participants in this study thoroughly dis-
cussed their quality of life. They have mentioned the
most important aspects in their lives and that have been
related to their experience of living with VL-HIV coin-
fection. The ability to work and earn money to sustain
their daily subsistence was described as a major compo-
nent of their quality of life. Qualitative studies on well-
being of HIV infected patients in some of the developing
countries including Ethiopia, mentioned similar theme
and determinants of wellbeing found in our study group.
Food, money, shelter, health, family relations, children
and education were commonly considered important for
wellbeing in population groups [14, 15].
The availability of VL treatment has had a significant
impact on QoL of coinfected patients. Most of the
patients who received AmBisome and combination with
oral Milefosine for VL treatment reported slight side
effects. Those who had experienced side effects said that
they got relief within a couple of days and that they felt
much better. Some of the participants who had a history
of VL reported that a reduction therapeutic response of
VL treatment and this results high rates of relapses.
These findings were supported by other quantitative
studies that are conducted on long term effectiveness
and treatment outcomes of VL-HIV coinfected patients
treated with AmBisome [16]. The VL-HIV coinfected
patients showed initial cure following treatment with
AmBisome but these patients appear to have much
higher rates of VL relapse and mortality than patients
not known to be HIV-positive.
Access to the VL-HIV treatment centers has had a
contribution to the positive changes in livelihoods of
some VL-HIV coinfected patients and it results hopeful-
ness for their future. There were similarities in the desire
expressed by the majority of hopeful respondents to gain
money for opening mini shop to sustain their income
and changing their living environment to non VL
endemic areas. This finding is supported by a study from
South Africa that elaborates in further details on how
HIV patients regained health and social relations while
in care [17]. Whereas some of the participants in our
study were not hopeful about their future, this finding
also in line with the study participants in rural Uganda
struggled to “get back to normal” and rebuild their social
life’s after diagnosis of HIV and treatment [18]. The
present study took place in VL-HIV coinfection treat-
ment facilities. All of the patients offered free treatments
for both VL and HIV infections. Half of the included
patients were newly diagnosed VL-HIV coinfected
patients. Indeed, some even reported a frequent relapse
of VL after they are attending the treatment center.
Therefore, life disruption was experienced by some of
our study participants.
Majority of the study participants’ who were in ART
demonstrate that they continue to quietly suffer from
stigmatization, stress, poverty, uncertainty about the fu-
ture and an inability to make known their HIV status.
Participants reported experiences of varying degrees of
stigma. These results are similar to those of other studies
in both developing countries [15, 19] and developed
world [20]. These challenges surrounding social stigma
and non-disclosure of HIV status negatively affected re-
spondents’ QoL. However, those study participants who
had not been on ART treatment during data collection
were not reported about stigmatization. The reason for
this is we included newly HIV diagnosed patients and
they didn’t have exposure with the community with
known HIV status.
The limitation of this study is clearly stated by the fol-
lowing statements. All interviews were conducted by the
PI and this may have introduced some bias however tape
record were played for the study participants and con-
firmed by their signature and transcripts were also
reviewed by colleagues. The present study participants
were only male migrant daily laborers this may also
introduce some bias. The reason for not including
female sex was the difficulty of finding infected female
migrant daily laborers. Interviews were tape recorded
and this may also have introduced some bias because
some of the interviewees were not comfortable with the
audio recorder practice due to stigma and non dis-
closure of the status.
Conclusion
This study highlights the complexities and multi-
dimensional nature of QoL and provided the challenges
and concerns faced by those VL-HIV coinfected male
patients in an African setting. Challenges of living envir-
onment and therapeutic response of VL treatment are
factors that most negatively affect the QoL of VL-HIV
coinfected patients. Engaging the unemployed males
who are desperately migrating to VL endemic and high
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HIV prevalent areas for job with micro-finance pro-
grams and giving technical support to help them create
their own job will not only improve the quality of life of
the already VL-HIV coinfected individuals but also will
alter the transmission dynamics of both HIV and VL. It
is possible to plan control programs specific to the
endemic areas if the unpredictable nature of the migra-
tion dynamics is not interfering with the policy and
programmatic planning and intervention. Clinical trials
aiming at reducing side effects and improving efficacy
should be encouraged. HIV prevention programs and
HIV positive-living counseling programs should target
migrant workers to VL endemic areas in the country.
Despite the free treatment of VL-HIV coinfected patients
provided by the treatment facilities found in Northwest
Ethiopia, those who faced a frequent relapse of VL experi-
enced life disruption. Although some participants spoke
hope for the future, there are fundamental factors that
cause adverse impact on QoL of VL-HIV coinfected pa-
tients. These factors were relapse of VL, stress, stigma,
poverty and depression. These factors need to be targeted
and addressed when managing these patients.
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